Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants
Status:
Not yet recruiting
Trial end date:
2025-07-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the long-term safety and efficacy profile of LTP001
in participants with pulmonary arterial hypertension (PAH). The study offers participants who
had completed the CLTP001A12201 double-blind parent study in PAH an opportunity to receive
LTP001 (whether they were on LTP001 or not). Unblinding of the treatment received in
CLTP001A12201 is generally not needed, but can occur on request by the investigator.